Buy Rating Affirmed for Zevra Therapeutics Based on Strong NPV and Future Market Potential

Summary

William Blair analyst Sami Corwin maintains a bullish stance on biotech firm Zevra Therapeutics, highlighting its valuation and future potentials. Despite typical biotech risks, Corwin sees further upside in clinical projects, citing valuation and leadership experience as key positives. Tags like 'Valuation' and 'Corwin' align with his analytical approach to Zevra's market trajectory.